Last reviewed · How we verify
American mucocutaneous leishmaniasis
Approved treatments
- Impavido · Knight Theraps
Impavido works by inhibiting the RAC-alpha serine/threonine-protein kinase, which is essential for the survival of Leishmania parasites.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- American mucocutaneous leishmaniasis patent landscape — cliff calendar, originator estates, attackable patents
- American mucocutaneous leishmaniasis treatment landscape brief
- American mucocutaneous leishmaniasis treatment updates RSS
Frequently asked questions about American mucocutaneous leishmaniasis
What drugs treat American mucocutaneous leishmaniasis?
Tracked treatments include Impavido.
What is the treatment for American mucocutaneous leishmaniasis?
Standard treatment for American mucocutaneous leishmaniasis includes Impavido. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: American mucocutaneous leishmaniasis patent cliff · American mucocutaneous leishmaniasis CI report
- Treatment: Impavido · Knight Theraps
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing